Neuren Pharmaceuticals Advances Phase 3 Trial for Phelan-McDermid Syndrome

Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an announcement.

Neuren Pharmaceuticals announced the confirmation of primary endpoints for its Phase 3 trial of NNZ-2591 in Phelan-McDermid syndrome (PMS) following a productive meeting with the FDA. This pivotal trial, set to commence mid-2025, marks a significant step forward as the first-ever Phase 3 trial for PMS in children, aiming to address the unmet medical needs in this area. The trial will assess improvements in receptive communication and overall symptom changes, building on positive results from Phase 2 trials. Neuren’s financial stability ensures no additional funding is required for the trial, highlighting its strong position in advancing treatments for rare neurological disorders.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited is engaged in developing new drug therapies for serious neurological disorders that manifest in early childhood and have limited or no approved treatment options. The company focuses on addressing urgent unmet medical needs, with all its programs receiving ‘orphan drug’ designation in the United States. Neuren’s drug DAYBUE™ (trofinetide) is approved for the treatment of Rett syndrome, and its second candidate, NNZ-2591, is being developed for multiple neurodevelopmental disorders.

YTD Price Performance: -10.04%

Average Trading Volume: 852

Technical Sentiment Signal: Buy

Current Market Cap: $739.6M

For detailed information about NEU stock, go to TipRanks’ Stock Analysis page.